The increases in research and development expenses for the quarter and nine months ended September 30, 2012, compared to the prior year periods were primarily a result of increased clinical development costs related to the advancement of the Company's pipeline and increased non-cash employee stock option expense. The Company expects its research and development expenses to vary from period to period, mainly due to the timing of its clinical development activities.Selling, general and administrative expenses for the quarter and nine months ended September 30, 2012, were $20.5 million and $61.6 million, respectively, as compared to $14.3 million and $37.1 million, respectively, for the same periods in 2011. Included in selling, general and administrative expenses for the quarter and nine months ended September 30, 2012, were non-cash expenses of $3.1 million and $9.8 million, respectively, related to the impact of expensing employee stock options, as compared to $2.6 million and $7.5 million, respectively, for the same periods in 2011.
Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders On Launch Of Jakafi And Lead Clinical Programs
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.